文献速递临床微生物分子诊断

法国商业定制微量稀释板用于人型支原体及脲原体药敏试验的评价与耐药流行率调查

Evaluation of commercial, customized microdilution plates for Ureaplasma parvum, Ureaplasma urealyticum, and Mycoplasma hominis antimicrobial susceptibility testing and determination of antimicrobial resistance prevalence in France.
PubMed 文献 · J Clin Microbiol · 2024-06-04

该研究用60株菌比较MICRONAUT-S板与CLSI参考微量稀释法,99.5%(679/680)的MIC结果一致。2020至2021年法国22家实验室收集临床标本,发现脲原体对左氧氟沙星和莫西沙星耐药率较2010至2015年显著上升,需持续监测。

要点

  • MICRONAUT-S定制板与CLSI参考法MIC符合率达99.5%,可用于人型支原体和脲原体药敏检测。
  • 法国2020至2021年脲原体对左氧氟沙星和莫西沙星耐药率较2010至2015年显著上升,需加强监测。
  • 微小脲原体对四环素耐药率(1.2%)显著低于解脲脲原体(11.8%)(P<0.001)。

核心结论

  • 定制MICRONAUT-S板是可靠、便捷的人型支原体、微小脲原体和解脲脲原体药敏试验工具。
  • 法国四环素和氟喹诺酮类耐药率仍有限,但脲原体对左氧氟沙星和莫西沙星耐药率从2010至2015年显著上升,需持续监测。

研究设计与样本

  • 方法学比较:用60株菌比较MICRONAUT-S板与CLSI参考微量稀释法的MIC结果。
  • 耐药流行率研究:2020年和2021年每年1个月,法国22家诊断实验室收集微小脲原体、解脲脲原体和人型支原体阳性临床标本,用MICRONAUT-S板测定MIC。
  • 耐药机制检测:PCR筛查tet(M)基因,PCR和Sanger测序筛查氟喹诺酮类耐药相关突变。

主要发现

  • MICRONAUT-S板与CLSI参考法的MIC符合率为99.5%(679/680)。
  • 90株人型支原体对四环素、左氧氟沙星和莫西沙星的耐药率分别为11.1%、2.2%和2.2%,无克林霉素耐药。
  • 248株微小脲原体对左氧氟沙星和莫西沙星的耐药率分别为5.2%和0.8%。
  • 68株解脲脲原体对左氧氟沙星和莫西沙星的耐药率分别为2.9%和1.5%。
  • 解脲脲原体对四环素耐药率(11.8%)显著高于微小脲原体(1.2%)(P<0.001),未观察到大环内酯类耐药。

关键数值与推荐

  • MICRONAUT-S板与CLSI参考法MIC符合率99.5%(679/680)。
  • 人型支原体四环素耐药率11.1%,左氧氟沙星和莫西沙星耐药率均为2.2%。
  • 微小脲原体左氧氟沙星耐药率5.2%,莫西沙星耐药率0.8%。
  • 解脲脲原体左氧氟沙星耐药率2.9%,莫西沙星耐药率1.5%,四环素耐药率11.8%。
  • 解脲脲原体与微小脲原体四环素耐药率差异有统计学意义(P<0.001)。

临床怎么用

  • 可采用MICRONAUT-S定制微量稀释板进行人型支原体、微小脲原体和解脲脲原体的药敏试验。
  • 对脲原体应关注左氧氟沙星和莫西沙星耐药,尤其是既往监测显示耐药率上升的趋势。
  • 四环素耐药在解脲脲原体中更常见,经验用药前宜参考药敏结果。

局限性

  • 方法学比较仅使用60株菌。
  • 耐药流行率研究仅覆盖2020年和2021年每年1个月的法国22家实验室标本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Antimicrobial susceptibility testing (AST) of human mycoplasmas using microdilution is time-consuming. In this study, we compared the performance of MICRONAUT-S plates (Biocentric-Bruker) designed for AST of Ureaplasma parvum, Ureaplasma urealyticum, and Mycoplasma hominis with the results using the Clinical & Laboratory Standards Institute (CLSI) reference method. Then, we investigated the prevalence and mechanisms of resistance to tetracyclines, fluoroquinolones, and macrolides in France in 2020 and 2021. The two methods were compared using 60 strains. For the resistance prevalence study, U. parvum-, U. urealyticum-, and M. hominis-positive clinical specimens were collected for 1 month each year in 22 French diagnostic laboratories. MICs were determined using the MICRONAUT-S plates. The tet(M) gene was screened using PCR, and fluoroquinolone resistance-associated mutations were screened using PCR and Sanger sequencing. Comparing the methods, 99.5% (679/680) MICs obtained using the MICRONAUT-S plates concurred with those obtained using the CLSI reference method. For 90 M. hominis isolates, the tetracycline, levofloxacin, and moxifloxacin resistance rates were 11.1%, 2.2%, and 2.2%, respectively, with no clindamycin resistance. For 248 U. parvum isolates, the levofloxacin and moxifloxacin resistance rates were 5.2% and 0.8%, respectively; they were 2.9% and 1.5% in 68 U. urealyticum isolates. Tetracycline resistance in U. urealyticum (11.8%) was significantly (P < 0.001) higher than in U. parvum (1.2%). No macrolide resistance was observed. Overall, the customized MICRONAUT-S plates are a reliable, convenient tool for AST of human mycoplasmas. Tetracycline and fluoroquinolone resistance remain limited in France. However, the prevalence of levofloxacin and moxifloxacin resistance has increased significantly in Ureaplasma spp. from 2010 to 2015 and requires monitoring. IMPORTANCE: Antimicrobial susceptibility testing of human urogenital mycoplasmas using the CLSI reference broth microdilution method is time-consuming and requires the laborious preparation of antimicrobial stock solutions. Here, we validated the use of reliable, convenient plates designed for antimicrobial susceptibility testing that allows the simultaneous determination of the MICs of eight antibiotics of interest. We then investigated the prevalence and mechanisms of resistance of each of these bacteria to tetracyclines, fluoroquinolones, and macrolides in France in 2020 and 2021. We showed that the prevalence of levofloxacin and moxifloxacin resistance has increased significantly in Ureaplasma spp. from 2010 to 2015 and requires ongoing monitoring.

来源:J Clin Microbiol,查看原文。版权归原作者所有。

引用

  1. Pereyre S, Hénin N, Dolzy A, et al. Evaluation of commercial, customized microdilution plates for Ureaplasma parvum, Ureaplasma urealyticum, and Mycoplasma hominis antimicrobial susceptibility testing and determination of antimicrobial resistance prevalence in France. J Clin Microbiol. 2024. PMID: 38832769. doi:10.1128/jcm.00226-24

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。